본문으로 건너뛰기
← 뒤로

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical Mutations: A Phase Ib Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 Vol.44(10) p. 893-902

Zhou H, Zhao H, Hou X, Wang Y, He Z, Li Y, Ma Y, Zhao Y, Huang Y, Chen L, Xiao S, Zhu H, Zhu Y, Fang W, Zhang L, Yang Y

📝 환자 설명용 한 줄

[PURPOSE] To evaluate the safety and efficacy of izalontamab brengitecan (iza-bren) in patients with non-small cell lung cancer (NSCLC) harboring actionable genomic alterations (GAs) outside of classi

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 14

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Zhou H, Zhao H, et al. (2026). Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical Mutations: A Phase Ib Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 44(10), 893-902. https://doi.org/10.1200/JCO-25-01929
MLA Zhou H, et al.. "Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical Mutations: A Phase Ib Study.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 44, no. 10, 2026, pp. 893-902.
PMID 41779981

Abstract

[PURPOSE] To evaluate the safety and efficacy of izalontamab brengitecan (iza-bren) in patients with non-small cell lung cancer (NSCLC) harboring actionable genomic alterations (GAs) outside of classical epidermal growth factor receptor () mutations.

[METHODS] Eligible patients had locally advanced or metastatic NSCLC with prespecific actionable GAs, had progressed after standard treatment and received no more than one previous line of chemotherapy. iza-bren was administered at the dose of 2.5 mg/kg once per day on days 1 and 8 of each 3-week cycle. The primary end point was safety. The secondary end points included objective response rate (ORR), disease control rate (DCR), and duration of response. The exploratory end points included progression-free survival (PFS) and overall survival (OS).

[RESULTS] A total of 83 patients with NSCLC were enrolled in four cohorts: exon20ins/nonclassical mutations (n = 14), human epidermal growth factor receptor 2 () mutation (n = 19), // mutation (n = 26), and /// fusion (n = 24). The most common grade ≥3 treatment-related adverse events (TRAEs) were thrombocytopenia (51.8%), anemia (44.6%), and neutropenia (43.4%). The most frequent nonhematologic TRAEs of all grades were nausea (49.4%), asthenia (45.8%), stomatitis (44.6%), and diarrhea (38.6%). One case of grade 2 interstitial lung disease was observed. The confirmed ORR was 39.7%, and the DCR was 85.9%. The median PFS was 7.0 months (95% CIs, 5.4 to 10.5), while OS data were immature. Patients with exon20ins or other nonclassical mutations achieved an ORR of 69.2% with a median PFS of 10.5 months (95% CI, 6.9 to not reached); the -mutant cohort had an ORR of 52.9% and a median PFS of 7.5 months (95% CI, 5.4 to not reached).

[CONCLUSION] iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse GAs outside of classical mutations, especially in exon20ins/nonclassical and mutations.

MeSH Terms

Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Female; Male; Middle Aged; Aged; Mutation; ErbB Receptors; Adult; Aged, 80 and over; Crown Ethers; Progression-Free Survival

같은 제1저자의 인용 많은 논문 (5)